基本信息
views: 29
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Professor Craddock will take a lead role in developing high-quality research programmes in clinical and cost effectiveness research of cancer therapies and support the University’s work on Innovation particularly in the health theme including the development of the University’s supra-regional health innovation campus Arden Cross and other projects.
He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society Of Haematology in 2017. He led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015 and in 2017 oversaw the £3.4m expansion of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.
Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukaemia’s, and he leads the UK Haemato-oncology Trials Acceleration Programme. He pioneered the development of a UK stem cell transplant trials network, IMPACT, one of only two worldwide, which was launched in 2017.
He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society Of Haematology in 2017. He led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015 and in 2017 oversaw the £3.4m expansion of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.
Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukaemia’s, and he leads the UK Haemato-oncology Trials Acceleration Programme. He pioneered the development of a UK stem cell transplant trials network, IMPACT, one of only two worldwide, which was launched in 2017.
Research Interests
Papers共 561 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Kriti Verma,Wayne Croft,Sandra Margielewska-Davies,Hayden Pearce, Christine Stephens, Diana Diaconescu, Sarah Bevington,Charles Craddock,Rasoul Amel-Kashipaz,Jianmin Zuo,Francesca AM Kinsella,Paul Moss
Blood Advances (2024)
The EBMT Handbookpp.617-631, (2024)
Sarah E. Hughes,Christel McMullan,Olalekan Lee Aiyegbusi,Karen Shaw,Francesca Kinsella, Paul Ferguson, Foram Khatsuria,David Burns, Lester Pyatt, John Ansell, Evelyn Chakera, Julie Richardson-Abraham,
BMJ OPENno. 3 (2024): e085392-e085392
Journal of Clinical Oncologyno. 15 (2024): 1731-1733
Nicholas McCarthy,Gege Gui,Florent Dumezy,Christophe Roumier,Georgia Andrew, Sarah Green, Madeleine Jenkins, Alexandra Adams,Naeem Khan,Charles Craddock,Christopher S Hourigan,Adriana Plesa,
Leukemia (2024)
HemaSphereno. 7 (2023): 791-800
BONE MARROW TRANSPLANTATIONno. SUPP1 (2023): 54-55
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 568
#Citation: 16584
H-Index: 65
G-Index: 117
Sociability: 8
Diversity: 3
Activity: 67
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn